• br Material and methods br Results br

  2025-02-11

  

  Material and methods Results Discussion The present study demonstrates for the first time that Mino selectively induces apoptosis in Jurkat alkylation of dna via an H2O2 signaling-dependent mechanism. Structurally, Mino is composed of a C10 and C12 phenol group, C12a hydroxyl group, and C1

• Picroside II br Consequences of central apelin APJ modulatio

  2025-02-11

  

  Consequences of central apelin/APJ modulation Regarding extra-hypothalamic actions, recent data demonstrate that the central apelin/APJ system could be a potential new target for the regulation of memory (Han et al., 2014). Then, intracerebroventricular (icv) apelin administration in mice impairs

• Recently whey products have been added to nutritional bevera

  2025-02-11

  

  Recently, whey products have been added to nutritional beverages to boost their antioxidant capacity. Supplementation of a lemon drink with 1% WP hydrolyzed by subtilisin increased the antioxidant activity of the beverage from 0.75 to 7.79 mmol of TE/L (Athira et al., 2014). In addition, a flavored

• br Acknowledgements We thank the National Natural

  2025-02-11

  

  Acknowledgements We thank the National Natural Science Foundation of China (41576156), Shandong Province Science and Technology Development Plan (2015GSF121045), Yantai Science and Technology Development Plan (2015ZH078), and the Public Science and Technology Research Funds Projects of Ocean (No.

• The most common grade AEs associated with the

  2025-02-11

  

  The most common grade 3/4 AEs associated with the soluble fusion protein ziv-aflibercept are neutropenia, hypertension, and diarrhea [63]. In general, medical oncologists associate ziv-aflibercept with worse toxicity than BV, and meta-analyses of clinical trial data with ziv-aflibercept or BV suppor

• First the complete canonical brain original

  2025-02-11

  

  First, the complete canonical brain original RAS (Angiotensinogen, Renin, Angiotensin I, Angiotensin Converting Enzyme (ACE), Angiotensin II) has not been conclusively identified in any specific cell type within the brain [1]. Validated evidence for the presence of brain Angiotensinogen and ACE was

• br Acknowledgement Work in the McEwan Laboratory is funded

  2025-02-11

  

  Acknowledgement Work in the McEwan Laboratory is funded by the Chief Scientist Office of Scottish Government: Grants ETM-258 and ETM-382. BE is supported by an Erasmus scholarship (D -JENA01). Introduction The equine placenta is a noninvasive transient organ, classified as diffuse and epithel

• Here we provide evidence that

  2025-02-11

  

  Here, we provide evidence that NO contributes to changes in synaptic strength, but also offer an explanation as to why previous attempts to link NO to LTP have often failed. Our results describe a model by which cycling AMPARs, held in intracellular pools, are rapidly delivered to the membrane surfa

• br Conflicts of interest br Funding

  2025-02-11

  

  Conflicts of interest Funding Introduction Brassicaceae is an economically important family of plants containing rapeseed, cabbage, broccoli, brussels, radish and mustard. Among them rapeseed plays a crucial role, because of its application in food and also in fuel industry. According to th

• It has been reported that NLRP product

  2025-02-11

  

  It has been reported that NLRP3 product, caspase-1, is increased in the brains of AD patients and experimental AD animals. NLRP3- and caspase-1-deficient animals are resistant to experimental development of AD, and have decreased IL-1β production and significantly increased Aβ clearance (Heneka et a

• br Discussion To our knowledge this is

  2025-02-11

  

  Discussion To our knowledge, this is the first case report that demonstrates the presence of a novel T1151K ALK mutation in a patient with disease progression after crizotinib and then ceritinib. As early as 2011, Zhang et al. identified T1151K among other resistance mutations to crizotinib in Ba

• br Development of lorlatinib from crizotinib to a clinical

  2025-02-11

  

  Development of lorlatinib from crizotinib (1) to a clinical candidate (6) Xalkori (1, PF-02341066, crizotinib), was the first-in-class ALK inhibitor approved by the Unites States Food and Drug Administration (FDA) in 2011 as a first-line treatment for ALK+- NSCLC patients. This section describes

• Activation of AhR is also known to

  2025-02-10

  

  Activation of AhR is also known to upregulate the expression of AhRR (AhR repressor), an inhibitor protein of AhR [29]. However, the exact mechanism by which AhRR represses AhR signaling is not well understood. The initial study by Mimura and colleagues suggested that AhRR is capable of directly com

• br Introduction Psychostimulant abuse and addiction remain a

  2025-02-10

  

  Introduction Psychostimulant abuse and addiction remain a societal problem in the United States. The latest statistics from the National Survey on Drug Use and Health indicate that slightly less than one million people over the age of 12 report having a cocaine use disorder (NSDUH, 2016). Additio

• Isochlorogenic acid B receptor Phosphodiesterase inhibition

  2025-02-10

  

  Phosphodiesterase inhibition increases the intracellular levels of cAMP to restore spontaneous contraction (Essayan, 2001, Qi and Kwan, 1996), acting downstream of adenylyl cyclase. Therefore, cardiac arrest induced by decreased intracellular cAMP levels could be reversed by phosphodiesterase inhibi

14826 records 14/989 page Previous Next First page 上5页 1112131415 下5页 Last page